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Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Its prevalence ranges 10–24% in the
general population, reaching 60–95% and 28–55% in obese and diabetic patients, respectively. Although the etiology of NAFLD
is still unclear, several lines of evidences have indicated a pathogenetic role of insulin resistance in this disorder. This concept has
stimulated several clinical studies where antidiabetic drugs, such as insulin sensitizers including metformin, have been evaluated
in insulin-resistant, NAFLD patients. These studies indicate that metformin might be of beneﬁt in the treatment of NAFLD, also
in nondiabetic patients, when associated to hypocaloric diet and weight control. However, the heterogeneity of these studies still
prevents us from reaching ﬁrm conclusionsabout treatment guidelines. Moreover, metformin could have beneﬁcial tissue-speciﬁc
eﬀects in NAFLD patients irrespective of its eﬀects as insulin sensitizer.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon cause of chronic liver disease. It includes a broad spec-
trum of liver alterations, ranging from pure steatosis to
cirrhosis, through nonalcoholic steatohepatitis (NASH).
NAFLD is characterized by liver damage and functional
impairment similar to those observed in alcoholic liver dis-
ease although occurring in patients who do not drink or
drink only a moderate amount of alcohol [1].
Although the pathogenesis of the disorder is not fully
clariﬁed, insulin resistance is widely considered a pivotal
feature of NAFLD,which is strongly and independentlyasso-
ciatedwith increased risk oftype2diabetesmellitus(T2DM)
and cardiovascular disease [2]. In the past, the diagnosis of
NAFLDwas mostly the result of ultrasound investigations or
liver function tests performed at random. Nowadays, the
great attention paid to the occurrence of metabolic syn-
drome and its related aspects has allowed us to put more
emphasis on diagnosis and treatment of this disorder. Clin-
icians have now become to pay attention to early diagnosis
and treatment of NAFLD in insulin-resistant obese and
T2DM patients. Diet and lifestyle changes are a mainstay in
the management of these patients, while speciﬁc pharma-
cologic treatment for NAFLD is so far lacking. Therefore,
it is not surprising that several studies have evaluated the
eﬃcacy of insulin sensitizers in NAFLD patients. Among
insulin sensitizers, metformin has recently acquired a central
roleinthetreatmentofT2DMandotherdisordersassociated
with insulin resistance, such as polycystic ovary syndrome
(PCOS), and both experimental and clinical studies have
recently supported the use of metformin as a useful adjunct
in NAFLD patients.
We will review evidences concerning a possible use of
metformin in the treatment of NAFLD.
2.Epidemiologyand RiskFactors
Epidemiological studies on NAFLD are limited by the lack
of a universal screening method used for diagnosis and by
the presence of various deﬁnitions and diagnostic criteria.
However, NAFLD has been reported to occur in 10–24% of
the general population [3, 4], thus, representing the most
common cause ofelevatedliverenzymes and one ofthemost
common forms of liver disease in the world. The occurrence
of NAFLD is increasing not only in Western countries, but2 Experimental Diabetes Research
also in Eastern countries, where evidence of steatosis at
liver ultrasounds (USs) is found in 16–30% of the general
population [1]. Moreover, NAFLD is increasingly diagnosed
in children and adolescents together with the concomitant
increase in obesity. Small epidemiologicalstudies havefound
that NAFLD occurs in 2.6–25% of obese children [5].
Asalreadymentioned,NAFLDisstronglyassociated with
insulin resistance and other components of the metabolic
syndrome, like T2DM, central obesity, hyperlipidemia,
hypertension,andwithotherconditionsassociated toinsulin
resistance, such as hyperuricemia, atherosclerosis, and PCOS
[6, 7].F orth i sr ea s on ,N AFL Di sn o wr ega r deda sth eh epa ti c
manifestation of the metabolic syndrome, aﬀecting up to a
third of the general population [3, 4]. In fact, the occurrence
of NAFLD is reported to range 28–55% in T2DM patients,
60–95% in obese patients, and 27–92% in hyperlipidemic
patients[8].Moreover,thestrongestassociation ofNAFLDis
with central adiposity, which is an important risk factor even
in patients with a normal body mass index (BMI). Diet, lack
ofexercise,and possiblysmall bowelbacterialovergrowthare
candidate factors inﬂuencing the risk of NAFLD [3]. Finally,
several studies have reported a potential role of genetic fac-
tors for the development of NAFLD. However, these studies
have limitations and must be interpreted with caution [3].
3.Pathogenesis
The pathogenesis of NAFLD is still object of discussion.
The prevailing hypothesis is based on the “two hits” model,
proposed by Day and James in [9]. The “ﬁrst hit,” char-
acterized by free fatty acid and triglyceride accumulation
in liver (steatosis), is caused by insulin resistance (through
lypolysis and hyperinsulinemia) and obesity (through leptin
resistance). This induces a chronic inﬂammatory condition
characterized by the release of proinﬂammatory cytokines
and by oxidative stress, both of which are responsible of the
“second hit,” which induces the progression from steatosis
to more advanced stages of liver damage (steatohepatitis and
ﬁbrosis). The “two hit” model has been recently challenged
because an increased ratio of saturated-to-unsaturated fatty
acids delivered to or stored within the liver may, in part,
mediate the progression from simple steatosis to NASH.
Proof of this concepthas been provided by recent data show-
ing that when triacylglycerol (TAG) precursors accumulate
in the liver and the mechanisms of hepatic detoxiﬁcation
are overwhelmed or inactive, saturated fatty acids directly
induce hepatic inﬂammation and insulin resistance both
of which may result in steatosis progression toward more
severe stages of liver disease [10]. Although the molecular
mechanisms that mediate the eﬀects of saturated fatty acids
are still unclear, it has been suggested that free fatty acidsand
TAG metabolites (fatty acyl-CoA, diacylglycerol, ceramide)
directlyorviaToll-likereceptors2and4(TRL2and4)induce
endoplasmatic reticulum stress, mitochondrial disfunction,
ROSproduction,impaired hepaticproteinmetabolism,inhi-
bition of insulin signaling, and activation of inﬂammatory
pathways (NF-κB, JNK, IKK) [11]. Moreover, as suggested
by novel evidences, fatty liver releases in the circulation
factors called hepatokines (i.e., fetuin A, sex hormone-
binding globulin (SHBG), and selenoprotein P) that are
directly involved in the pathogenesis of local and system
inﬂammation and in peripheral and hepatic insulin resis-
tance[12].However,itisimportanttoemphasizethatinsulin
resistance remains a key player in NAFLD pathogenesis and
that fatty liver may, in turn, potentiate insulin resistance.
It remains controversial whether NAFLD may contribute to
insulin resistance independently of the eﬀect of age and total
adiposity [13]. Studies showing that liver fat content aﬀects
insulin sensitivity in humans more strongly than visceral fat
[14, 15] support a direct and important role of fatty liver in
the pathogenesis of insulin resistance.
4.Diagnosis
NAFLDis essentially an asymptomatic condition. In patients
with NAFLD, who do not have advanced liver disease, the
most common sign on physical examination is hep-
atomegaly, and the diagnosis is made when a US or radio-
logical test reveals evidence of fatty liver. Mild to moderated
elevationofALT,AST,orbotharethemostcommonﬁndings
(with the AST: ALT ratio <1) [16]. However, liver enzymes
may be normal in up to 78% of patients, and; thus, enzyme
elevation is insensitive for the detection of NAFLD [17].
The diagnosis of NAFLD is made after exclusion of other
causes of liver disease, such as alcohol abuse, viral hepatitis,
autoimmune disorders. Older age, obesity, T2DM are risk
factors suggesting potential NAFLD diagnosis. Abdominal
US is currently the most common method employed for
qualitative assessment of hepatic steatosis, because it is
noninvasive and widely available.
Both computerized tomographic (CT) scanning and, in
particular,magneticnuclearresonance(MNR)imagingseem
to be more sensitive techniques for the quantiﬁcation of liver
steatosis. However, none of these imaging techniques have
suﬃcient sensitivity and speciﬁcity for staging the disease,
and they cannot distinguish between simple steatosis and
ﬁbrosis [18]. Liver biopsy still remains the gold standard
for distinguishing between the broad range of chronic
liver diseases, but it is limited by its cost, the potential
risk of bleeding, and the absence of consensus regarding
the histopathological criteria that ﬁrmly deﬁne NASH and
diﬀerentiate between NAFLD entities [19].
Given the high prevalence of NAFLD, it would be
desirable to use in clinical practice a more practicable and
noninvasive diagnosticmethod. Inarecentstudy,USshowed
high sensitivity (91.7%) and speciﬁcity (100%) in detecting
fatty liver [20], and a recent review conﬁrmed that US can
accuratelyidentifysteatosis with asensitivityand aspeciﬁcity
of 80–100% [19]. Moreover, the accuracy of US in detecting
steatosis seems to be unaﬀected by obesity [21]. Finally, a
recent prospective study [22] demonstrated that serial liver
US is an accurate tool for noninvasive monitoring of eﬃcacy
of interventions in NAFLD patients.
4.1. Emerging Diagnostic Tools. There is mounting evidence
that cytokines secreted not only from adipose tissue, namely,Experimental Diabetes Research 3
adipokines, but also from hepatocytes in response to liver
injury, are involved in the pathogenesis of NAFLD as well as
in its progression [23]. Clinical studies suggest that serum
levels of leptin, resistin, adiponectin, tumor necrosis factor
α (TNF α), interleukin-6 (IL-6), visfatin, CK-18, and retinol
bindingprotein4(RBP4)diﬀeramong patientswith NAFLD
and NASH and healthy controls [24–26].
To overcome biopsy limitations, noninvasive methods
have been developed and validated for diﬀerentiating simple
fatty liver from NASH and for predicting the risk of NAFLD
evolution to NASH. These alternative surrogate markers of
liver ﬁbrosis include liver stiﬀness measurements (LSMs),
using the method of transient elastography (Fibroscan) [27]
and various algorithms, among which the NAFLD ﬁbrosis
score [28], the BAAT score [29], and the HAIR score [30],
all based on biochemical and clinical parameters. These
algorithms have all been developed as simple noninvasive
scoring systems aimed at separating patients with NAFLD
with and without advanced liver ﬁbrosis by using routinely
determined and easily available clinical and biochemical
variables [28].
However, currently, the debate is also open on this issue,
and new studies are needed.
5.StrategiesinNAFLDManagement
The ﬁrst-line treatment of NAFLD is currently based on diet
and lifestyle modiﬁcations. Most of the published studies in
NAFLD population have shown that gradual weight loss (5–
10%), calorie-restricted diet, and regular physical exercise
lead to a decrease in the incidence of metabolic syndrome,
improvement in liver enzyme proﬁle, and resolution of
hepatic steatosis [31–34]. However, most of these studies
are nonrandomized and short term. Therefore, the paucity
of data has limited the production of diet and exercise
evidence-based guidelines for NAFLD patients. Moreover,
dietary treatment is limited by the lack of compliance and
the frequent regain of weight at followup [35].
A pharmacological treatment in patients with NAFLD
is not universally accepted yet. Given that insulin resistance
plays a key role in the pathogenesis of NAFLD, many studies
have evaluated the use of insulin sensitizers as a possible
treatment for this disease. Biguanides (metformin) and thi-
azolidinediones (TZDs), including pioglitazone and rosigli-
tazone, are the two classes of insulin sensitizers studied in
humans [23].
Several trials have shown a beneﬁcial eﬀect of TZDs in
patients aﬀected by NAFLD. Three studies, two open-label
and one placebo-controlled trial, have evaluated the eﬃcacy
ofrosiglitazoneinNAFLDpatients[36–38].Allofthesestud-
ies have reported an improvement in transaminases levels
and hepatic inﬂammation. However, nowadays rosiglitazone
has been removed from the market because of its signiﬁcant
side eﬀects.
The secondthiazolidinedioneavailableforthetimebeing
is pioglitazone. Four small trials and a large-controlled trial
have been conducted to evaluate its eﬃcacy in the treat-
ment of NAFLD [38–42]. In the largest controlled trial,
Belfort et al. [40] compared diet plus pioglitazone to diet
plus placebo in 55 patients. The pioglitazone-treated group
showed an improvement in ALT (by 50%), steatosis (by
54%), insulin sensitivity (by 48%), liver inﬂammation, and
ballooning necrosis but not ﬁbrosis. An improvement in
ﬁbrosis was seen only in one of the small four studies
mentioned above [41]. Signiﬁcant amelioration of liver bio-
chemistry, steatosis, and liver inﬂammation has been also
reported in the multicenter placebo-controlled trial called
PIVENS [43] (pioglitazone versus Vit E and versus placebo),
in which NASH nondiabetic patients were treated for 96
weeks with pioglitazone (30mg daily). Even if all of these
studies have demonstrated the usefulness of pioglitazone in
NAFLD,thisdrughasonlybeenusedinpatientswithbiopsy-
proven NASH. Furthermore, the long-term safety of this
drug is not yet well established. For this reason, today the
use of pioglitazone in some countries has been restricted
for possible unknown long-term side eﬀects [44]. Another
insulin sensitizer that could be used in NAFLD patients is
metformin. Its eﬃcacy and usefulness will be extensively
discussed in the next paragraph.
6.Roleof MetformininNAFLD
6.1. Mechanism of Action of Metformin. Metformin was in-
troduced in clinical practise in the 1950s and is widely used
as aﬁrst-line treatment for patientswithtype 2 diabetesmel-
litus [45]. The eﬀectiveness of metformin as an antidiabetic
drug is explained by its ability to lower blood glucose by
decreasing gluconeogenesis in the liver, stimulating glucose
uptake in the muscle, and increasing fatty acid oxidation in
adipose tissue [46]. The ﬁnal eﬀect is an improvement of
peripheral insulin sensitivity. At molecular level, some of the
beneﬁcial eﬀects of this drug have been related to the phos-
phorylation and nuclear export of LKB1. This latter kinase
activates adenosine monophosphate-activatedproteinkinase
(AMPK), a regulator of energy metabolism, able to stimulate
ATP-producing catabolic pathways (glycolysis, fatty acid
oxidation,andmitochondrialbiogenesis)andtoinhibitATP-
consuming anabolic processes (gluconeogenesis, glycogen,
fatty acid, and protein synthesis) [47]. Upon activation in
response to energy stress, in the muscle, AMPK induces
hexokinase II expression and GLUT4 gene upregulation and
translocation to cell membrane, leading to an increase in
glucose uptake. Furthermore, it phosphorylates and inhibits
glycogen synthase, thereby, inducing a decrease in glycogen
synthesis. In the liver, AMPK reduces hepatic gluconeoge-
nesis by inducing the phosphorylation of CREB-binding
protein (CBP) and, as consequence, the dissociation of the
gluconeogenic CREB-CBP-TORC2 transcriptional complex
[45]. This event, mediated by atypical protein kinase C (PKC
ι/λ), triggers the disassembly of the transcription machinery
and the inhibition of the expression of gluconeogenesis
enzyme genes including phosphoenolpyruvate carboxyki-
nase (PEPCK) and glucose-6-phosphatase (G6Pase). The
activation of AMPK by metformin exerts beneﬁcial eﬀects
also on lipid metabolism. Indeed, upon metformin-induced
phosphorylation, AMPK inactivates acetyl-CoA carboxy-
lase (ACC) and 3-hydroxy-3-methylglutaryl (HMG)-CoA4 Experimental Diabetes Research
reductase, decreases fatty acid synthase (FAS) expression,
and activates malonyl-CoA carboxylase. The ﬁnal eﬀect is
a decrease in fatty acid and cholesterol synthesis. More-
over, AMPK inhibits the sterol regulatory element-binding
protein-1c (SREBP-1c), which is a transcription factor for
genes involved in fatty acid synthesis [48]. SREBP-1c is
induced by an excess of glucose and insulin and is inappro-
priately increased in NAFLD patients. Recent ﬁndings show
that the eﬀect of metformin in counteracting adipose tissue
expansion occurs not only through a direct inhibition of
adipogenesis but also by modulating adipokine synthesis or
secretion [49]. Indeed, adiponectin, induced by metformin,
directly stimulates AMPK and prevents hepatic lipid accu-
mulation by increasing β-oxidation of free fatty acids and/or
by decreasing their de novo synthesis. Furthermore, in ob/ob
mice, a model of hepatic steatosis, it has been shown that
metformin reversedhepatomegaly, hepaticfat accumulation,
and ALT abnormalities, by reducing hepatic tumor necrosis
factor-α (TNF-α) expression [50].
Although AMPK is the main player in mediating met-
formin eﬀects, it is important to note that some metabolic
actions of metformin occur in AMPK-independent manner
and may be mediated by MAPK- and PKA-dependentmech-
anisms. Asithasbeenshown byZhang et al. [51],metformin
exerts an inhibitory eﬀect on catecholamine-stimulated
lipolysis through decreasing cAMP production and reducing
PKA and MAPK activities.
Aschematicrepresentation ofthemolecularmechanisms
of metformin actions in peripheral tissues is shown in
Figure 1.
6.2. Clinical Studies with Metformin. Several clinical trials
have supported the beneﬁcial role of metformin in patients
with NAFLD (Table 1). Most of these studies have evaluated
the eﬀect of various doses of metformin on liver biochem-
istry (aminotransferase proﬁle), histology, and metabolic
syndrome features [35, 47, 52–59]. In 2001, Marchesini et al.
[52] conducted the ﬁrst pilot nonrandomized study using
metformin (1.5g day for 4 months) in 20 NASHnondiabetic
patients. They observed a signiﬁcant improvement in insulin
resistance, aminotransferase levels, and liver morphology
and volume in the treated group compared to the diet
group. However, the study showed as limitation the fact
that no follow-up biopsies were performed, and, thus, the
histological improvement was not evaluated. Another small
metformin versus diet trial, conducted in 17 randomized
nondiabetic patients receiving metformin (850mg twice a
day), showed no diﬀerences in liver biopsies between treated
and untreated groups. By contrast, ALT, AST, body mass
index, and insulin resistance markers improved signiﬁcantly
in the metformin-treated group in comparison to controls
[54].
Six open-label trials [47, 53, 55, 57, 58, 60]h a v ee v a l -
uated the liver histology modiﬁcation together with serum
aminotransferase levels and insulin resistance markers’ ame-
lioration in NAFLD patients treated with metformin (dose
ranging from 1.4g/day to 2.0g/day and treatment duration
varying from 24 to 48 weeks) alone or in association with
other drugs. All these studies reported an improvement
in the indices of insulin resistance: ﬁve studies reported a
reduction in liver function test values and one reported a
non-signiﬁcant increase of these values [53]. In terms of
histological improvement, only three trials [47, 55, 57]
showed signiﬁcant diﬀerences in inﬂammation, steatosis,
and ﬁbrosis after treatment with metformin. In contrast
to these promising results, some recent open-label studies
have found no beneﬁt ofmetformin treatment (doseranging
from 1.5g to 1.7g/day and for a period of 6–12 months) on
liver steatosis, aminotransferase levels, and insulin resistance
markers compared to lifestyle changes or control untreated
group [59, 61, 62]. However, these latter studies were
conducted in small series of patients. Furthermore, these
controversial results could be due to the diﬀerent duration
and dose of the treatment and to the variable time periods
between the ﬁrst and the second biopsy.
Recently, we have conducted a prospective randomized
study in which we evaluated the eﬃcacy of the addiction
of low dose of metformin (500mg twice a day) to dietary
treatment (1300 kcal) in 50 obese and nondiabetic patients.
Wefoundthatmetforminplusdietarytherapywasassociated
with an improvement or even disappearance of hepatic
steatosis similar to what observed with diet treatment alone.
Metformin treatment was also associated with a signiﬁ-
cantly greater amelioration of several metabolic parameters
(increased insulin sensitivity and reduced fasting glucose)
than diet alone. Fasting glucose, basal serum insulin, and
HOMA-IR index values decreased in both groups. However,
diﬀerences both in fasting glucose (from 92.4 ± 9.9 to 89.1 ±
9.3mg/dL, P = 0.04) and HOMA-IR index (from 3.3 ± 1.6
to 2.4 ± 1.2, P = 0.003) reached statistical signiﬁcance only
in the metformin group.
At baseline, impaired fasting glucose (IFG) was found
in approximately 35% NAFLD patients in both groups. At
the end of the study, IFG disappeared in 86% of metformin
treated patients and in 62% of patients receiving only
diet treatment. Metformin treatment was also signiﬁcantly
more eﬀective than diet alone in reducing the proportion
of patients who met the diagnostic criteria of metabolic
syndrome (20% reduction in the metformin group, P =
0.0008versus4%reductioninthedietgroup,P = 0.9).Given
the high proportion of NAFLD patients with metabolic syn-
drome and the association between metabolic syndrome and
type 2 diabetes mellitus (T2DM) and cardiovascular diseases
[1, 41], our results suggest that a low dose of metformin
mightbeproposedtoNAFLDpatients,especiallyiftheymeet
the diagnostic criteria of metabolic syndrome [35].
The potential role of metformin has also been examined
in pediatric patients with NAFLD. Results in pediatric pop-
ulation were similar to those of adults and supported the
beneﬁcial eﬀects of metformin on biochemistry liver proﬁle
and metabolic parameters, but not on histological features.
The ﬁrst study was conducted by Schwimmer et al. [63],
who tested metformin (1g/day) in ten insulin-resistant chil-
dren with biopsy-proven steatohepatitis, for a period of
24 weeks. More recently, Naideau et al. [64]r a n d o m -
ized ﬁfty obese and insulin-resistant adolescents to receive
lifestyle recommendations plus metformin (850mg twice a
day for 6 months) or placebo. In both studies the treatmentExperimental Diabetes Research 5
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Figure 1: Metformin action in peripheral tissues. Metabolic eﬀects of metformin are mainly mediated through the activation of adenosine
monophosphate-activated protein kinase (AMPK), a master regulator of glucose and lipid metabolism. In skeletal muscle, metformin
increases glucose uptake by enhancing the atypical protein kinase C (PKC) ι/λ-dependent glucose transporter (GLUT4) translocation to
the cell membrane, while, in liver, metformin-dependent activation of PKC ι/λ reduces gluconeogenic enzyme gene expression through the
dissociation of the CREB-CBP-TORC2 complex via CREB binding protein phosphorylation. In liver, muscle, and adipose tissues, AMPK
decreases cholesterol and fatty acid synthesis and increases fatty acid oxidation by inhibiting the enzymes acetyl-CoA carboxylase (ACC),
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase and fatty acid synthase (FAS) and activating the malonyl-CoA carboxylase (M-CoA).
Moreover, it downregulates the sterol regulatory element-binding protein-1c (SREBP-1c), which is a transcription factor for lipogenetic
genes.In adiposetissue,metformininhibitslipolysisthrough attenuation ofPKAandERK1/2 signaling.Itmayalsoimpact onthe endocrine
functionofadipose tissue,throughmodulationofadipokines synthesis orsecretion, probably inanAMPK-dependent manner.Adiponectin
also activates AMPK, thereby, enhancing metformin action.
with metformin resulted in serum aminotransferases, liver
fat, and insulin sensitivity improvements as compared
with untreated or placebo-treated group.
In another small observational trial conducted for 24
months in ten obese-overweight children with NAFLD [65],
metformin (1.5g/day) did not appear more eﬀective than
lifestyle intervention in ameliorating levels of aminotrans-
ferases and liver histology, but it signiﬁcantly improved
metabolic parameters and HOMA index. Similar results
were obtained in a larger randomized multicenter placebo-
controlled trial called the TONIC (Treatment of Nonalco-
holic Liver Disease in Children) in which 57 children with
NAFLD were treated with metformin (1g/day) for 96 weeks.
The study demonstrated that metformin is not superior to
placebo in attaining a sustained reduction in ALT levels and
signiﬁcant improvements in histological features [66].
Althoughthese clinicaltrials havesometimes shown con-
troversial results, probably because they have generally been
small, short term, and with often inconsistent outcomes,
it is undoubted that metformin, by improving metabolic
features of NAFLD, does show promise in the management
of this liver disease. However, further larger randomized
controlled trials of suﬃcient duration and using histological
endpoints are needed to assess the eﬀectiveness of this drug
in modifying the natural history of NAFLD.
7.A Rationalforthe Use of
M etformininN AFLD
7.1. Eﬀects on Metabolic Abnormalities and Cardiovascular
Risk. As previously mentioned, NAFLD is now considered
a hepatic manifestation of the metabolic syndrome. Patients
with NAFLD frequently have many clinically signiﬁcant co-
morbidities, suchasobesity,impairedglucosetolerance,type
2 diabetes, hypertension, and hyperlipidemia (high fasting
serum triglyceride and LDL levels and low HDL values).
The complex of these pathological conditions leads to an
increased cardiovascular risk [23]a n dm a yc o n t r i b u t et ot h e
progression of hepatic damage. The therapeutical approach
to NAFLD, therefore, aims at ameliorating these metabolic
derangements, all linked to insulin resistance.
Treatment with aninsulin-sensitizing agent, such asmet-
formin,maycorrectseveralofthesecomponentsofthemeta-
bolic syndrome. Moreover, in diabetic patients, metformin
provides cardiovascular protection that cannot be attributed6 Experimental Diabetes Research
Table 1: Summary of metformin trials in NAFLD/NASH patients.
References Study design Patients Therapy Outcomes
Marchesini et al. [52]O L , S A20 patients, (OB); NASH,
elevated AMTs
Metformin 1.5g/d; 4
months
↓ ALT
↓ IR
↓ liver volume
Nair et al. [53]O L , S A
28 patients,
(OW/OB/T2DM);
NAFLD
Metformin 20mg/kg/d;
12 months
↓ ALT and AST
↓ IR
Histology improved
Uygun et al. [54]O L , R A N D 36 patients, (OW/OB);
NASH, elevated AMTs
Metformin 1.7g/d + diet
versus diet; 6 months
↓ IR
↓ ALT and AST
Histology not
improved
Bugianesi et al. [55] OL, RAND
(MC)
110 patients,
(OW/OB/T2DM);
NAFLD, elevated AMTs
Metformin 2g/d + diet
v e r s u sv i tE+d i e tv e r s u s
die; 12 months
↓ AST and ALT
Histology improved
Schwimmer et al. [63]S A
10 patients (OB/NT2DM
children); NASH, elevated
AMTs
Metformin 1g/d; 6
months
↓ AST and ALT
↓ Liver fat
↓ IR
Duseja et al. [56]O L , N R A N D 50 patients, (OW/OB);
NAFLD, elevated AMTs
Metformin 1.5g/d; 6
months versus diet
↓ ALT and AST
↓ IR
Loomba et al. [47]O L , S A
28 patients,
(OW/OB/T2DM);NASH,
elevated AMTs
Metformin 2g/d; 12
months
Histology improved
↓ ALT and AST
↓ IR
de Oliveira et al. [57]O L , S A
20 patients,
(OW/OB/T2DM);NASH,
elevated AMTs
Metformin 1g/d; 12
months
↓ ALT
Histology improved
↓ IR
Idilman et al. [58]O L , R A N D
74 patients,
(OW/OB/T2DM);NASH,
elevated AMTs
Metformin 1.7g/d; 12
months
↓ ALT
Histology not
improved
↓ IR
Nobili et al. [65]O L 57 patients (OW/OB
children); NASH/NAFLD
Metformin 1.5g/d versus
diet; 24 months
↓ ALT and AST
↓ IR
Histology improved
Haukeland et al. [59]P L A C , R A N D
48 patients
(OW/OB/T2DM);
NAFLD, elevated AMTs
Metformin versus
placebo; 6 months
↓ ALT and AST
↓ IR
Histology not
improved
Nadeau et al. [64]R A N D 50 patients (OB children);
NAFLD/elevated AMTs
Metformin 1.7g/d + diet
versus diet; 6 months
↓ ALT and AST
↓ IR
Ultrasound pattern
improved
Garinis et al. [35]O L , R A N D 50 patients, (OW/OB);
NAFLD, normal AMTs
Metformin 1g/d + diet
versus diet; 6 months
↓ ALT and AST, ↓ IR
Ultrasound pattern
improved
↑ Adiponectin
Abbreviations: ALT, alanine transaminase; AMTs, aminotransferases;AST, aspartate aminotransferase; IR, insulin resistance; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis; NRAND, non randomized; NT2DM, non type 2 diabetes mellitus; OB, obese; OL, open label; OW, overweight;
PLAC, placebo controlled; RAND, randomized; SA, single arm; T2DM, type 2 diabetes mellitus.
only to its antihyperglycemic eﬀects. These additional car-
dioprotective eﬀects may be related to the favorable actions
of metformin on lipid metabolism, vascular smooth-muscle
and cardiomyocyte intracellular calcium handling, endothe-
lial function, hypercoagulation, and platelet hyperactivity
[67].
Metformin therapy may result in a signiﬁcant antihyper-
tensive eﬀects [68], which include both insulin-dependent
and insulin-independent vasodilatory actions and probably
also central antihypertensive eﬀects [69]. Several authors
have shown that metformin improves lipoprotein proﬁles
with a decrease in low-density lipoprotein (LDL) cholesterol
levels, triglycerides, and high-density lipoprotein (HDL)
cholesterol levels[3]. Metforminhasbeenreported toreduce
markers of inﬂammation and to lessen hypercoagulation
and increase ﬁbrinolysis by decreasing levels of plasminogen
activator inhibitor-1 and increasing tissue plasminogen acti-
vator activity. Metformin also improves functional andExperimental Diabetes Research 7
biochemical markers of endothelial reactivity as well as
surrogate indexes of coronary atherosclerosis [67]. Another
relevant mechanism is the reduction of circulating advanced
glycatedendproducts(AGEs),which areoxidativemediators
of endothelial dysfunction. Moreover, metformin is able to
stimulate intracellular AMPK and to activate the endothelial
isoform of NOSs in human aortic endothelial cells [70].
7.2. Eﬀects on Weight Loss. The reported prevalence of obe-
sity in patients with NAFLD varies from 30 to 100% [8]a n d
increases with increasing BMI. An analysis of liver histology
suggests that the prevalence rates of steatosis and steato-
hepatitis are approximately 15% and 3%, respectively, in
nonobese persons, while they increase to 65% and 20%,
respectively, in patients with class I-II obesity (BMI: 30.0–
39.9kg/m2) and to 85% and 40%, respectively, in extremely
obese patients (BMI: ≥40kg/m2)[ 71].
These data support the rationale of using metformin,
which help reducing body weight in obese patients with and
without diabetes [72–75] and inducesa signiﬁcant reduction
in total body fat and visceral fat [74]. Weight loss during
metformin treatment has been attributed to decreased net
caloric intake [76], probably through appetite suppression,
an eﬀect largely independent of gastrointestinal side eﬀects
of metformin [73]. Reduction in hyperinsulinemia related
to reduced insulin resistance may have an additive eﬀect
on weight reduction in obese, insulin-resistant patients [77–
79].
It has been reported that even a modest weight loss can
produce improvements in markers for NAFLD, namely, ALT
and imaging markers of liver fat [80, 81].
In the Diabetes Prevention Program, metformin use was
associated with a small improvement in ALT levelsovertime.
Weight loss appeared to be the dominant mediator of this
eﬀect, and the 4-year cumulative incidence for development
of abnormal ALT values was lowest in patients who lost the
most weight [82].
7.3. Eﬀects on Glucose Disorders. The prevalence of T2DM
in NAFLD varies from 10 and 75% [8], and this condition
is the only independent variable associated with advanced-
stage NAFLD [13]. Indeed, the great frequency of impaired
fasting glucose and impaired glucose tolerance in NAFLD
requiresatherapeuticapproachwhich delaysandreducesthe
onset of diabetes. Metformin therapy contributes to pro-
tect pancreatic β-cell reserve and delay diabetes by low-
ering blood glucose and reducing peripheral insulin resis-
tance.
In a large randomized placebo-controlled trial, the Dia-
betes Prevention Program (DPP) recently showed that im-
provement in insulin sensitivity, through either intensive
lifestyle modiﬁcation or metformin, reduces the risk of
developing T2DM in high-risk individuals [83]. Data ob-
tained in the same population demonstrated that metformin
does not mask the development of diabetes but provides a
curative eﬀect on glucose derangement [78].
Recently, we compared the eﬃcacy of a treatment with
low-dose metformin and dietary measures alone in obese,
nondiabetic patientswith NAFLDina 6-month, prospective,
randomized study. After therapy, the proportion of patients
with impaired fasting glucose declined from 35 to 5% (P =
0.04) in the metformin group, a proportion signiﬁcantly
higher in respect to the control group [35].
7.4. Eﬀects on Polycystic Ovary Syndrome. PCOS represent a
very common condition aﬀecting 6-7% of reproductive aged
women [84].Insulin resistance has a pivotalrolein ovulatory
disfunction and androgen excess and represents a strong
pathogenetic link with metabolic abnormalities associated
with metabolic syndrome and NAFLD. Moreover, the preva-
lence of NAFLD in PCOS women ranges from 30 to 60%
[85].
The pleiotropic action of metformin makes it a ﬁrst-
line medical therapy in PCOS women. Metformin decreases
ovary production of total and free testosterone levels and
improves follicular growth with both an indirect action,
through the reduction of hyperinsulinemia, and a direct
action on ovarian tissue, through the increase in AMPK and
a reduction in CYP17 activity [84]. Clinically, metformin
therapy improves hirsutism and normalizes menstrual cycles
and induces ovulation in PCOS patients [67]. In PCOS,
this approach with metformin introduced a pharmaceutical
option targeting various aspects of this syndrome, which
were previously neglected but that may contribute to adverse
cardiometabolic outcomes.
7.5. Eﬀects on Cancer Risk. T2DM and obesity are associated
with an increased risk of a variety of cancers [86–91], while
weight controlisassociated witha decreasedcancerrisk [92].
Recent data have elucidated some molecular mechanisms by
which insulin resistance is involvedin cancer [93]. Moreover,
metabolic syndrome is associated with a worsen cancer out-
come [94].
Hepatocellular carcinoma (HCC) is a complication of
NAFLD-associated cirrhosis, and the majority of “crypto-
genic”HCCintheUnitedStatesisattributedtoNAFLD[94].
Both T2DM and metabolic syndrome are also associated
with HCC. However, it is unclear whether NAFLD predis-
poses patients to HCC in the absence of cirrhosis. Studies
supported evidence that HCC may develop in NAFLD unac-
companied by cirrhosis [95].
These observations have several implications in NAFLD
prevention and treatment: ﬁrst because early treatment of
NAFLD plays a role in primary prevention of HCC and sec-
ond because metformin, itself may have an antitumor eﬀect
both in vitro and in vivo [91, 96]. In fact, T2DM patients,
who are prescribed metformin, have a lower risk of cancer
compared to patients that are not treated with metformin
[97, 98].
The upstream regulator of AMPK is a protein kinase
known as LKB1, a well-recognized tumor suppressor. Acti-
vation of AMPK by metformin and exercise requires LKB1,
and this would also explain why exercise is beneﬁcial in the
primary and secondary prevention of certain cancers [97].
Metformin is known to activate AMPK and to inhibit
cyclin D1 expression and proliferation of cultured cancer8 Experimental Diabetes Research
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Figure 2: Schematic representation of NAFDL diagnosis and management. No consensus is available for the use of insulin sensitizers
(metformin and pioglitazone), although studies have generally shown beneﬁcial eﬀects. The US Food and Drug Administration (FDA)
has recently released a note to inform that the use of pioglitazone for more than one year may be associated with an increased risk of
bladder cancer. In France the use of pioglitazone has been suspended while in Germany it is recommended not to start pioglitazone in
new patients. Scanty data are available with regard to the eﬃcacy of statins and hepatoprotective agents. Liver ultrasonography, the most
practicable method for NAFLD detection is actually used to monitor response to treatment although not yet validated. Liver function tests
may be useful despite a poor sensibility for NAFLD diagnosis and disease monitoring. Metabolic parameters still represent viable indexes of
response to therapy.
cells. However, the mechanisms of action by which met-
formin mediates cell cycle arrest are not completely under-
stood [99].
In a retrospective case-control study performed in 465
HCC patients, it has been found that T2DM is an indepen-
dent risk factor for HCC and pre-exists in the majority of
HCCpatients. Moreover, in patients with T2DM, there was a
direct association of HCC with insulin and sulphonylureas
treatment and an inverse relationship with metformin
therapy[100]. In addition, the predictivevalue ofhyperinsu-
linemia in total cancer mortality [101] and fatal liver tumor
incidence [102] has been demonstrated in nondiabetic sub-
jects by two recent prospective studies.
8.Monitoring theEfﬁcacyof Metformin
Therapyin NAFLD
As we previously mentioned, most studies with metformin
show an improvement in liver aminotransferases and liver
histology. However, it is still unclear what is the best way to
monitor the response to therapy in NAFLD patients. In fact,
despite an increase in transaminases is common in NAFLD,
liver enzymes may be normal in up to 78% of patients and,
thus, are insensitive not only for NAFLD diagnosis but also
for disease monitoring. On the other hand, although liver
biopsy is still considered the gold standard for distinguishing
between the broad range of chronic liver diseases [19],Experimental Diabetes Research 9
it has several limitation, including cost, the potential risk
of bleeding, and the absence of consensus regarding the
histopathological criteria that ﬁrmly deﬁne NASH and dif-
ferentiate between NAFLD entities [8, 103]. Accordingly,
a repeated liver biopsy after a short term therapeutic trial
is considered too invasive and impracticable to be applied
in clinical practice, especially when considering the high
prevalence of the disease [5].
Liver ultrasonography, the most practicable method for
NAFLD detection, is not yet validated to monitor response
totreatment. Thus,newsensitiveand noninvasivemarkers of
response are needed. As already mentioned, several markers
have been proposed, such as ﬁbrosis score and cytokines, but
remain yet to be validated. Therefore, metabolic parameters
still represent viable indexes of response to therapy.
9.EmergingConceptsand CandidateFuture
TherapiesinNAFLD
SincetheetiologyandpathogenesisofNAFLDarenotentire-
ly clariﬁed, new therapies await future developments in our
understanding of key pathogenetic mechanisms of NAFLD.
Ongoing research is exploring novel approaches that look
promising in preclinical models.
MicroRNAs(miRNAs)havebeenrecentlystudiedinarat
model of NAFLD [104] and in cultured human hepatocytes
[105] and seem to have an important role in hepatic
energy metabolism and in the pathophysiological process of
NAFLD. Several miRNAs are dysregulated in NAFLD, and
this contributes to dysregulation of genes involved in hep-
atocyte proliferation, apoptosis, inﬂammation, and glucose
and lipid metabolism [106]. The developmentof an eﬀective
and safe approach for correcting miRNA dysregulation is a
new challenge for NAFLD therapy.
Novel chemically engineered oligonucleotides, termed
“antagomirs,” have been shown to be eﬃcient and speciﬁc
silencers of endogenous miRNAs [107]. Particularly, both
in monkeys [108]a n di nm i c e[ 107], antagomir against
miRNA-122 resulted in a reduction of hepatic steatosis. A
phase I study in humans is ongoing [106].
The regulation of AMPK activity is another emerging
molecular target for the treatment of NAFLD. Pharmacolog-
ical AMPK activators are being developed for the treatment
of multiple metabolic disorders including NAFLD. Beside
glucose homeostasis, AMPK also regulates hepatic lipid
metabolism [106]. AMPK activation by AICAR or alpha-
lipoic acid has been shown to decrease liver fat content in
lean and obese rodents [109, 110]. These preclinical data
need conﬁrmation in human trials.
Decreased levels of glucagon-like peptide 1 (GLP-1) are
commoninobesepatients[111],andreducedincretinaction
has been demonstrated in nondiabetic, nonobese patients
with NASH, thus, prompting evaluation of GLP-1 analogs
in fatty liver [106]. In obese mice, exendin, a GLP-1 agonist,
mayameliorateinsulin resistance and decreasehistologicste-
atosis [112]. Only one case report illustrates a similar eﬀect
in humans [113]. Appropriate trials are, therefore, needed to
asses the potential use of GLP-1 agonists in NAFLD [111].
In conclusion results of preclinical studies on emerging
therapy of NAFLD are encouraging, but further work is
needed to evaluate the eﬃcacy and safety of these new agents
in humans.
10.ConclusiveRemarks
No drug is currently available as speciﬁc treatment for
NAFLD, and no drug can substitute for lifestyle modiﬁca-
tion. However, available evidences clearly show a pivotal role
of metformin in improving metabolic alterations associated
with NAFLD.Therefore, metformin, because ofitsmetabolic
eﬀects and its safety proﬁle, remains a promising drug in
NAFLDtherapy, especially in patientsthat meet the diagnos-
tic criteria of metabolic syndrome [35]. A schematic repre-
sentation of NAFLD diagnosis and management is shown in
Figure 2.
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